Revenue growth of 86% and fivefold exceeding the market growth rate – PROMOMED announces operational results for the 1st quarter of 2025

May 20, 2025, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly "PROMOMED", the "Company", and together with its subsidiaries, the "Group") announces the Group's operating results for the 1st quarter of 2025.

OPERATIONAL INDICATORS

• In Q1 2025, ahead of schedule, the Company launched the innovative drug Tirzetta® (INN tirzepatide), intended for the treatment of obesity and type II diabetes mellitus. Tirzetta® is the only direct competitor of the Mounjaro registered and designated in the USA on the Russian market. Sales of Tirzetta® in the reporting period amounted to more than 1 billion rubles, which confirms the high interest in the product from doctors and patients.
• The company continues to demonstrate growth rates that significantly outpace the growth rates of the pharmaceutical market.:

- In Q1 2025, the evolution index[3] of the Endocrinological Portfolio was 116.1 (outstripping the growth of the relevant market of 9 INN by more than 16 percentage points).
- In Q1 2025, the index of the evolution of the Oncological Portfolio amounted to 220.4 (outstripping the growth of the relevant market by 29 INN by more than 120 percentage points). This result reflects the high demand for the Company's drugs and confirms the strategic importance of this therapeutic area.
- In Q1 2025, the evolution index for Other drugs in the Base Portfolio was 154.2 (ahead of the growth of the relevant market of 162 INN by more than 54 percentage points).

• In Q1 2025, the Company conducted 51 medical studies.
• In Q1 2025, the Company received registration certificates for 6 medicines.
• In Q1 2025, the Company registered 10 new patents. The increase in the number of intellectual property objects reflects the commitment of the ongoing strategy to bring innovative drugs to the market and confirms the steady expansion of the intangible asset portfolio.

FINANCIAL INDICATORS

• According to management reports, in Q1 2025, the Company's revenue increased by 86% to 4,485 million rubles. The Company's revenue growth rate is more than five times higher than the growth rate of the pharmaceutical market, which grew by 16%.
• The share of revenue from the sale of innovative products increased to 69%, which is almost 11 percentage points higher than a year earlier (58% for Q1 2024).
• The share of Endocrinological and Oncological portfolios in revenue for Q1 2025 was 65% (40% for Q1 2024), due to the faster growth rates of these segments, as well as the introduction of new drugs to the market.
• The company continues to focus on the most promising segments of the pharmaceutical market.:

- In the Endocrinology segment, revenue for Q1 2025 increased by 171% compared to Q1 2024 and amounted to 1.6 billion rubles, primarily due to the successful sales of new products – Quincenta®, Velgia® and Tirzetta®.
- In the Oncology segment, revenue for Q1 2025 increased by 252% compared to Q1 2024 and amounted to 1.3 billion rubles. The main growth driver was the introduction of new drugs to the market.

• The company confirms its financial forecast for 2025: revenue growth of 75% with an EBITDA margin of>40%.

Alexander Yefremov, CEO of PJSC PROMOMED, commented:
"We confidently follow the strategy of innovative development, offer fresh solutions in all areas where PROMOMED operates: we develop and launch new medicines and technologies, introduce innovative patient support programs, and are the first to create and use newly developed financial products.

Of course, such an impressive result is based on technologically mature full-cycle production, well-established internal processes for the development, transfer, production and commercialization of new products of the Company.

We are simultaneously accelerating the creation of innovations and scaling the business.

All this combined, combined with the efforts of a team of talented professionals, makes it possible to boost the growth forecasts familiar to markets."

About the Company

PJSC PROMOMED is a leading innovative biopharmaceutical company with the potential for significant growth in promising segments of the pharmaceutical market. In 2025, PROMOMED celebrates the 20th anniversary of the Company's founding.

The Company's structure includes its own unique world-class R&D center and a high–tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company develops a diversified portfolio of more than 350 medicines in the TOP 10 segments of the pharmaceutical market. The Company's portfolio includes "blockbuster" drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on the ownerThe Company produces drugs for the treatment of socially significant diseases: oncology, diabetes, obesity, neurology, infectious diseases, rheumatology, etc. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the Company is an active participant in the system of ensuring national drug safety and import independence of the country.

Contacts

For investors	For the media
ir@promomed.pro	pr@promomed.pro

Statement of limitation of liability
This message and the information contained therein are not:

• an offer to purchase any securities,
• an invitation to make offers for the purchase of any securities,
• as part of such offers or invitations,
• securities advertising in the Russian Federation or other jurisdictions,
• by encouraging or recommending transactions,
• it is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED (hereinafter referred to as the Company) is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the sole source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page.https://e-disclosure.ru/portal/company.aspx?id=38533.

The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions contained in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). The indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.
The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.

3%">
[1] Hereafter: financial indicators according to management reporting data

[2] According to IQVIA

[3] Evolution Index (EI) is an evolution index calculated to assess the progress of a product and/or a company's product portfolio in the market, reflecting the growth rate of a product compared to the growth of its relevant market. Values above 100 indicate by how many percentage points the product or portfolio is growing faster than the market